The HIFα (hypoxia inducible factor alpha) transcription factors are the key mediators of the hypoxia response 1 . HIFα protein dysregulation in cancer can be triggered by mutation of the von-Hippel Lindau (VHL) gene, an event that hinders the negative control of HIFα protein stability through the ubiquitin ligase activity of VHL. This idea has been validated for HIF2α, the HIF isoform preferentially upregulated in VHL-mutant tumours and which has recently been implicated as driver of cancer stem cells 2-5 . However, signalling events that link the stem cell-intrinsic transcriptional machinery to pivotal mechanisms of HIF2α regulation in cancer remain to be charted.
The HIFα (hypoxia inducible factor alpha) transcription factors are the key mediators of the hypoxia response 1 . HIFα protein dysregulation in cancer can be triggered by mutation of the von-Hippel Lindau (VHL) gene, an event that hinders the negative control of HIFα protein stability through the ubiquitin ligase activity of VHL. This idea has been validated for HIF2α, the HIF isoform preferentially upregulated in VHL-mutant tumours and which has recently been implicated as driver of cancer stem cells [2] [3] [4] [5] . However, signalling events that link the stem cell-intrinsic transcriptional machinery to pivotal mechanisms of HIF2α regulation in cancer remain to be charted.
ID proteins (ID1 to ID4) are master regulators of stem cells that are hijacked during tumorigenesis and foster stem cell self-renewal and angiogenesis 6, 7 . Although the pro-tumorigenic role of ID proteins has been linked to the accumulation of mRNAs and proteins, it remains unclear whether other mechanisms exist that deregulate ID activity in cancer cells. Among ID proteins, ID2 is essential for tumour angiogenesis and glioma stemness and it is a component of the signature that predicts poor outcome in patients with high-grade glioma [8] [9] [10] .
We show that ID2 activity is restrained by DYRK1 kinase-mediated phosphorylation on Thr27 and hypoxia reduces this event by inhibiting DYRK1 activity. In hypoxic brain tumour cells, active ID2 binds to and disrupts the VHL complex, thus preventing ubiquitin-mediated proteasomal degradation of HIF2α. This is a previously unrecognized mechanism that fosters cancer stem cells and aggressiveness of human cancer.
Hypoxia regulates phosphorylation of ID2 by DYRK1
We used mass spectrometry to identify the phosphorylation sites of human ID2. Beside Ser5 (ref. 11) , we found that ID2 is phosphorylated on Ser14 and Thr27 (Extended Data Fig. 1a-c) . A sequencing analysis of the ID2 gene in cancer revealed that the colorectal cancer cell line HRT-18 harbours and expresses a mutant ID2(T27A) protein (Extended Data Fig. 2a, b ). Thr27 of ID2 is highly conserved throughout evolution (Extended Data Fig. 2c ). The primary role of ID proteins is to preserve stem cell properties, a function widely documented in neural stem cells (NSCs) 12, 13 . Therefore, to interrogate the significance of the ID2(T27A) mutation, we tested the selfrenewing capacity of ID2-null NSCs reconstituted with wild-type ID2 (ID2(WT)) or ID2(T27A) (Fig. 1a ). Introduction of ID2(T27A) in ID2-null NSCs increased neurosphere formation in serial passages by more than 50% when compared with ID2(WT) (P = 0.00883-0.000229; t ratio = 4.772-12.597) and caused a 2.4-fold increase in cell expansion rate (40.5 ± 1.7 versus 16.7 ± 0.831; P < 0.0001, Fig. 1b-d) . From the analysis of 18 candidate kinases, the dualspecificity tyrosine-phosphorylation-regulated kinases 1A and 1B (DYRK1A and DYRK1B) emerged as the only enzymes able to phosphorylate Thr27 of ID2 ( Fig. 1e, Extended Data Fig. 2d ). The sequence surrounding the Thr27 residue in ID2 resembles the DYRK1 phosphorylation consensus motif RX(X)(S/T)P and is highly conserved in different species (Extended Data Fig. 2c) 14 . Antibodies against a phospho-T27-ID2 peptide confirmed that ID2 is phosphorylated by wild-type kinase but not the inactive DYRK1B(K140R) kinase ( Fig. 1a , f-h) 15 . Endogenous and exogenous ID2 and ID2(T27A) co-precipitated endogenous DYRK1A and DYRK1B ( Fig. 1i and Extended Data Fig. 2e ). Treatment of glioma cells with harmine, a small-molecule inhibitor of DYRK1 (ref. 16 ), or combined short hairpin RNA (shRNA)-mediated silencing of DYRK1A and DYRK1B reduced Thr27 phosphorylation of ID2 ( Fig. 3e and Extended Data Fig. 2f ).
Next, we sought to identify the regulatory mechanisms controlling Thr27 phosphorylation of ID2. Exposure of human GBM-derived glioma stem cells (GSCs) to hypoxia or hypoxia-mimicking agent cobalt chloride (CoCl 2 ) caused loss of Thr27 phosphorylation ( Fig. 2a and Extended Data Fig. 3a ). Determination of the Thr27 phosphorylation stoichiometry of ID2 in the neuronal cell line SK-N-SN revealed that 21.08% of ID2 was phosphorylated on Thr27 in normoxia but the phosphorylation dropped to 2.28% in a hypoxic environment (Extended Data Fig. 3b, c) . Mirroring the reduction of Thr27 phosphorylation of ID2, CoCl 2 reduced DYRK1 kinase activity ( Fig. 2b and Extended Data Fig. 3d ) and DYRK1 auto-phosphorylation, an event Mechanisms that maintain cancer stem cells are crucial to tumour progression. The ID2 protein supports cancer hallmarks including the cancer stem cell state. HIFα transcription factors, most notably HIF2α (also known as EPAS1), are expressed in and required for maintenance of cancer stem cells (CSCs). However, the pathways that are engaged by ID2 or drive HIF2α accumulation in CSCs have remained unclear. Here we report that DYRK1A and DYRK1B kinases phosphorylate ID2 on threonine 27 (Thr27). Hypoxia downregulates this phosphorylation via inactivation of DYRK1A and DYRK1B. The activity of these kinases is stimulated in normoxia by the oxygen-sensing prolyl hydroxylase PHD1 (also known as EGLN2). ID2 binds to the VHL ubiquitin ligase complex, displaces VHL-associated Cullin 2, and impairs HIF2α ubiquitylation and degradation. Phosphorylation of Thr27 of ID2 by DYRK1 blocks ID2-VHL interaction and preserves HIF2α ubiquitylation. In glioblastoma, ID2 positively modulates HIF2α activity. Conversely, elevated expression of DYRK1 phosphorylates Thr27 of ID2, leading to HIF2α destabilization, loss of glioma stemness, inhibition of tumour growth, and a more favourable outcome for patients with glioblastoma.
Article reSeArcH T27-ID2   0   5   10   15   20   25   30 35
Per cent neurospheres *** 
T27A)
GST-ID2 GST-ID2(S5A) GST-ID2(S14A)
GST-ID2(T27A) GST Coomassie staining 32 
HIF1α
HIF2α p-T27-ID2 ID2 α-tubulin Similarly, exposure of GSCs to low oxygen decreased DYRK1A and DYRK1B tyrosine auto-phosphorylation ( Fig. 2c, d) .
Prolyl hydroxylases PHD1, PHD2 and PHD3 operate as direct sensors of cellular oxygen concentration 18, 19 . Immunoprecipitation using an antibody that recognizes hydroxyprolines indicated that DYRK1A and DYRK1B carry hydroxylated prolines, and CoCl 2 abrogated DYRK1 prolyl hydroxylation ( Fig. 2e ). DYRK1A and DYRK1B interacted in vivo with PHD1 ( Fig. 2f ) and the expression of PHD1 enhanced prolyl hydroxylation of both kinases (Extended Data Fig. 3h ). In particular, DYRK1B interacted with PHD1 through the kinase domain (Fig. 2g ). The activity of DYRK1A and DYRK1B towards Thr27 of ID2 was potentiated by PHD1 in vitro and in vivo ( Fig. 2h , i). Thus, oxygen deprivation induces a constitutively active ID2 by inactivating DYRK1 kinases, which are positively regulated substrates of PHD1.
Phosphorylation of ID2 by DYRK1 destabilizes HIF2α
We used human GSCs to interrogate the effects of DYRK1 and ID2(T27A) on HIF2α and glioma stemness. Lentiviral transduction of the DYRK1-resistant ID2(T27A) mutant in GSC line number 48 resulted in elevation of HIF2α and enhanced tumour sphere forming capacity as measured by limiting dilution assay (LDA, Extended Data Fig. 4a-d ). ID2(T27A)-induced accumulation of the HIF2α protein was independent of transcription (Extended Data Fig. 4e ). When detectable, HIF1α levels mirrored those of HIF2α but with more limited changes (Extended Data Fig. 4f ).
Expression of DYRK1 in GSC line number 34 and GSC line number 31 reduced HIF2α, the HIF2α target TGFα and the glioma stem cell marker SOX2 ( Fig. 3a and Extended Data Fig. 4g , h). Also in this case HIF2α mRNA was unchanged (Extended Data Fig. 4h , j). LDA and serial clonal experiments showed that the DYRK1-induced decrease of HIF2α attenuated glioma stemness ( Fig. 3b-d and Extended Data Fig. 4k ). However, accumulation of HIF2α, expression of SOX2 and the frequency of GSCs were restored by co-expression of DYRK1 and ID2(T27A) but not ID2(WT) ( Fig. 3a-d and Extended Data Fig. 4k ). DYRK1-mediated inhibition of gliomasphere formation was overridden by co-expression of non-degradable HIF2α (HIF2α-TM, TM, triple mutant; Extended Data Fig. 4l ) 20 . Furthermore, silencing of DYRK1A or DYRK1B upregulated HIF2α and reduced phosphorylation of Thr27 of ID2, with maximal effects after co-silencing of both kinases ( Fig. 3e ). Next, we investigated the effects of DYRK1 and ID2(T27A) on ubiquitylation and the stability of HIFα. DYRK1-mediated phosphorylation of Thr27 triggered HIFα ubiquitylation and expression of ID2(T27A) reversed DYRK1 effect ( Fig. 3f and Extended Data Fig. 5a ). Similarly, expression of DYRK1B prevented accumulation of HIF2α under hypoxia and co-expression of ID2(T27A) abrogated this response ( Fig. 3g ). DYRK1 accelerated the decay of HIF2α during recovery from exposure to CoCl 2 and reduced HIF2α half-life and ID2(T27A) counteracted these effects (Fig. 3h , i and Extended Data Fig. 5b , c).
ID2 binds and disrupts the VCB-Cul2 complex
Mass spectrometry analysis of ID2 immunoaffinity complexes revealed that Elongin C, a component of the VCB-Cul2 ubiquitin ligase complex that includes VHL, Elongin C, Elongin B, Cullin 2, and RBX1 is an ID2-associated protein ( Supplementary Tables 1 and 2 ). The direct interaction of ID2 with Elongin C and VHL was confirmed in vitro and in vivo ( Fig. 4a and Extended Data Fig. 5d , e). ID2 was unable to bind to HIFα proteins (Extended Data Fig. 5d ). VHL and Elongin C interacted strongly with ID2, weakly with ID1 and ID3, and did not bind to ID4 ( Fig. 4b and Extended Data Fig. 5f , g). The interaction between ID2 and VHL was mediated by the amino-terminal region of ID2 that includes Thr27 and did not require the HLH domain (amino acids 35-76, Fig. 4c ). A more detailed mapping of the regions involved in the VHL-ID2 interaction revealed that amino acids 15-35 of ID2 and the SOCS box of VHL (amino acids 154-174) were required for the binding (Fig. 4d, e ). Mutation of Lys159 (K159E), which provides the VHL contact surface for binding to Cul2 (refs 21, 22) , impaired the interaction with ID2 ( Fig. 4e ). Consistent with ID2 deletion mapping analysis, an ID2 peptide composed of amino acids 14-34 bound to both VHL and components of the VCB complex pre-assembled in insect cells. However, addition of a phosphate to Thr27 or mutation of Thr27 to a bulky hydrophobic amino acid (T27W) prevented the binding to both VHL and the VCB complex ( Fig. 4f and Extended Data Fig. 5h ). These findings were corroborated by computational molecular docking whereby a N-terminally-derived ID2 peptide (amino acids 15-31) docked preferentially to a groove on the molecular surface of VHL:Elongin C 22 with the N-terminal half of its interaction surface contacting the SOCS box of VHL that binds Cul2 (primarily Lys159) and the C-terminal half (including Thr27) fitting snugly into a hydrophobic pocket mostly contributed by the Elongin C surface (Extended Data Fig. 6a , c, d). Mutating Thr27 to phospho-Thr27 and re-docking resulted in unfavourable energy and displacement of the peptide from this location on the complex (Extended Data Fig. 6b ). DYRK1 disrupted the interaction between VHL and ID2(WT) but did not affect the binding of VHL to ID2(T27A) (Fig. 4g ). The phosphomimic ID2(T27E) mutant failed to bind VHL and did not promote accumulation of HIF2α (Extended Data Fig. 7a, b ). Next, we developed an in vitro assay using purified proteins that included bacterially expressed Flag-ID2, enzymatically active recombinant DYRK1B and baculovirus-expressed VCB-Cul2 complex or purified VHL. In this system, ID2 bound to VCB-Cul2 complex and VHL in the absence of active DYRK1B, but the interaction was disrupted by DYRK1-mediated phosphorylation of Thr27 ( Fig. 4h and Extended Data Fig. 7c ).
In the VCB-Cul2 complex, the Cul2 subunit provides the scaffold module for the interaction with the ubiquitin-conjugating enzyme (E2) 23, 24 . As we expressed ID2(T27A), ID2 was loaded onto VCB, and the Cul2/RBX1 module dissociated from the complex in the absence of changes in the total cellular levels of Cul2 and RBX1 ( Fig. 4i ). We also found that challenging the pre-assembled VCB complex with increasing 
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In vitro binding Article reSeArcH amounts of recombinant Flag-ID2 resulted in progressive dissociation of Cul2 (Fig. 4j ). Expression of ID2(T27A) triggered a comparable block of Elongin C-Cul2 association whereas it did not affect the assembly of a Cul5-based complex containing SOCS2, a SOCS protein that cannot bind to ID2(T27A) (Extended Data Fig. 7d, e ). Finally, in glioma cells in which ID2 and VHL are present at a molar ratio of 5.7:1 (Extended Data Fig. 7f ), hypoxia signalling promoted the association between endogenous VHL and ID2 while dissociating Cul2 ( Fig. 4k and Extended Data Fig. 7g ). Silencing of ID2 rescued the dissociation of Cul2 from VCB complex and prevented HIF2α elevation ( Fig. 4k ). Together, these findings indicate that ID2 activation stabilizes HIF2α by disabling VCB ubiquitin ligase via dissociation of Cul2.
A DYRK1-ID2 pathway controls HIF2α in glioma
To determine whether activation of ID2 enhances HIF2α transcriptional activity in an unbiased fashion, we used CINDy, an algorithm for high-fidelity reconstruction of post-translational causal dependencies to interrogate whether ID2 can affect the activity of HIF2α on its targets in the context of GBM 25 . When applied to a collection of 548 TCGA-derived GBM samples, ID2 activity emerged as the modulator of the transcriptional connection between HIF2α and its activated target genes ( Fig. 5a, b ). The activity of ID2 is estimated by the VIPER algorithm, a computational tool designed to infer protein activity from gene expression data 26 . When GBM samples were divided into two groups based on ID2 activity, samples with higher ID2 activity showed significantly stronger correlation between HIF2α and its targets than a set of random genes (P = 0.001, Fig. 5a ). This positive correlation was absent in the cohort of GBM with low ID2 activity (P = 0.093, Fig. 5b ). Consistent with these observations, we detected a marked reduction of HIF2α protein following acute deletion of the Id1 and Id2 genes in a mouse model of malignant glioma (Extended Data Fig. 8a) 9 . We interrogated the effect of DYRK1 expression in mouse models of human glioma. Tetracycline-induced expression of DYRK1B at levels comparable to normal brain (Extended Data Fig. 8b ), downregulated HIF2α in glioma cells in vitro and in sub-cutaneous xenografts and reduced the expression of the HIF2α targets that promote stem cell functions ( Fig. 5c-e ). Expression of DYRK1B also inhibited tumour cell proliferation in vivo, resulting in tumour reduction ( Fig. 5f and Extended Data Fig. 8c, d ). Next, we evaluated the anti-tumour effects of DYRK1B(WT) or the kinase inactive K140R mutant in an orthotopic model of glioma (Extended Data Fig. 8e ). Animals bearing glioma cells that expressed DYRK1B(WT) manifested significantly increased survival and tumour latency relative to mice bearing DYRK1B(K140R) or vector transduced cells (Fig. 5g, h ). Two out of seven mice in the DYRK1B(WT) group developed tumours that failed to express exogenous DYRK1B (Extended Data Fig. 8f ). This result suggests that active DYRK1 kinase is incompatible with tumour growth in this glioma model. Finally, higher DYRK1A and DYRK1B predicted a more favourable clinical outcome for GBM patients, thus supporting the clinical significance of DYRK1 activity in glioma ( Fig. 5i and Extended Data Fig. 9a ).
Discussion
Here we report a novel mechanism of functional inactivation of the VHL ubiquitin ligase that is independent of genetic mutations of the VHL gene. This mechanism is centred on the ability of active ID2 to disrupt the VCB-Cul2 complex, leading to HIF2α stabilization. We also unravel a hypoxia-directed cascade of events that by overriding the restraining effect of DYRK1-mediated phosphorylation of ID2 on Thr27, culminates with ID2 activation and HIF2α stabilization. The transcriptional activation of the ID2 gene, a HIFα target 27 , by HIF2α generates a feed-forward ID2-HIF2α loop that further supports cancer stem cells and glioma aggressiveness (Extended Data Fig. 10 ). By showing that PHD1-mediated prolyl hydoxylation enhances the enzymatic activity of DYRK1 kinases towards ID2, our findings provide a clue to the mechanism of DYRK1 inhibition in hypoxia. Thus, inhibition of DYRK1 kinases is an oxygen-sensing signal that disables VCB-Cul2.
The gene coding for DYRK1A is gained in Down syndrome, a disease characterized by impaired neural proliferation during β-actin Correlation enrichment score development [28] [29] [30] , reduced self-renewal and premature withdrawal from the cell cycle 31 . These findings are consistent with the notion that activation of DYRK1A and DYRK1B inhibits proliferation and activates a cellular quiescence program [32] [33] [34] [35] [36] [37] . It is plausible that DYRK1-activating signals are negative regulators of self-renewal of both normal and cancer stem cells. By phosphorylating ID2 on Thr27, DYRK1 weakens the core of the stemness machinery centred on the ID2-HIF2α pathway. We suggest that together with the control of ID2 activity, regulation of sonic hedgehog/Gli signalling and CREB-mediated transcription by DYRK kinases cooperate to restrain stem cell functions and tumorigenesis in the nervous system [38] [39] [40] . The glioma inhibitory effect of DYRK1 in the mouse, and the predictive value of DYRK1 expression on GBM patient survival support the tumour suppressor function of DYRK1 kinases in vivo. Whereas there is agreement on the negative role of DYRK1 towards stemness and cell proliferation 31, 35 , the broad spectrum of DYRK kinase substrates may account for the pro-tumorigenic functions of DYRK1 reported by other studies 41 . It has been proposed that loss of DYRK1 and accumulation of ID2 and HIF2α drive tumour progression of other cancer types beside GBM. The mechanism reported here might operate widely during the transition of cancer cells towards the more aggressive stem-like state that drives maintenance and progression of solid tumours.
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MethOdS Data reporting. No statistical methods were used to predetermine sample size. The investigators were not blinded to allocation during experiments and outcome assessment. Plasmids, cloning and lentivirus production. A constitutively stabilized mutant of HIF2α (HIF2α-TM) was obtained from Christina Warnecke 20 . The HIF2α-TM (triple mutant) construct harbours the following mutations in the prolyl and asparagyl hydroxylation sites: P405A, P530G and N851A. Polypeptide fragments of DYRK1B were cloned into pcDNA3-HA and include DYRK1B N terminus, N-Ter (amino acids 1-110), DYRK1B kinase domain, KD (amino acids 111-431), and DYRK1B C terminus, C-Ter (amino acids 432-629). cDNAs for RBX1, Elongin B and Elongin C were kindly provided from Michele Pagano (New York University) and cloned into the pcDNA vector by PCR. HA-tagged HIF1α and HIF2α were obtained from Addgene. GFP-tagged DYRK1A and DYRK1B were cloned into pcDNA vector. pcDNA-HA-VHL was provided by Kook Hwan Kim (Sungkyunkwan University School of Medicine, Korea). Site-directed mutagenesis was performed using QuickChange or QuickChange Multi Site-Directed mutagenesis kit (Agilent) and resulting plasmids were sequence verified. Lentivirus was generated by co-transfection of the lentiviral vectors with pCMV-ΔR8.1 and pMD2.G plasmids into HEK293T cells as previously described 9, 42 . ShRNA sequences are: ID2-1: GCCTACTGAATGCTGTGTATACTCGAGTATACACAGCATTCAGTAGGC; ID2-2: CCCACTATTGTCAGCCTGCATCTCGAGATGCAGGCTGACA ATAGTGGG; DYRK1A: CAGGTTGTAAAGGCATATGATCTCGAGATC ATATGCCTTTACAACCTG; DYRK1B: GACCTACAAGCACATCAATGA CTCGAGTCATTGATGTGCTTGTAGGTC. Cell culture and hypoxia induction. IMR-32 (ATCC CCL-127), SK-N-SH (ATCC HTB-11), U87 (ATCC HTB-14), NCI-H1299 (ATCC CRL-5803), HRT18 (ATCC CCL-244), and HEK293T (ATCC CRL-11268) cell lines were acquired through American Type Culture Collection. U251 (Sigma, catalogue number 09063001) cell line was obtained through Sigma. Cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Sigma). Cells were routinely tested for mycoplasma contamination using Mycoplasma Plus PCR Primer Set (Agilent, Santa Clara, CA) and were found to be negative. Cells were transfected with Lipofectamine 2000 (Invitrogen) or calcium phosphate. Mouse NSCs were grown in Neurocult medium (StemCell Technologies) containing 1× proliferation supplements (StemCell Technologies), and recombinant FGF-2 and EGF (20 ng ml −1 each; Peprotech). GBM-derived glioma stem cells were obtained by de-identified brain tumour specimens from excess material collected for clinical purposes at New York Presbyterian-Columbia University Medical Center. Donors (patients diagnosed with glioblastoma) were anonymous. Progressive numbers were used to label specimens coded in order to preserve the confidentiality of the subjects. Work with these materials was designated as IRB exempt under paragraph 4 and it is covered under IRB protocol #IRB-AAAI7305. GBM-derived GSCs were grown in DMEM:F12 containing 1× N2 and B27 supplements (Invitrogen) and human recombinant FGF-2 and EGF (20 ng ml −1 each; Peprotech). Cells at passage (P) 4 were transduced using lentiviral particle in medium containing 4 μg ml −1 of polybrene (Sigma). Cells were cultured in hypoxic chamber with 1% O 2 (O 2 Control Glove Box, Coy Laboratory Products, MI) for the indicated times or treated with a final concentration of 100-300 μM CoCl 2 (Sigma) as specified in figure legends.
Mouse neurosphere assay was performed by plating 2,000 cells in 35 mm dishes in collagen containing NSC medium to ensure that distinct colonies were derived from single cells and therefore clonal in origin 43 . We determined neurosphere formation over serial clonal passages in limiting dilution semi-solid cultures and the cell expansion rate over passages, which is considered a direct indication of self-renewing symmetric cell divisions 44 . For serial sub-culturing we mechanically dissociated neurospheres into single cells in bulk and re-cultured them under the same conditions for six passages. The number of spheres was scored after 14 days. Only colonies >100 μm in diameter were counted as spheres. Neurosphere size was determined by measuring the diameters of individual neurospheres under light microscopy. Data are presented as percent of neurospheres obtained at each passage (number of neurospheres scored/number of NSCs plated × 100) in three independent experiments. P value was calculated using a multiple t-test with Holm-Sidak correction for multiple comparisons. To determine the expansion rate, we plated 10,000 cells from 3 independent P1 clonal assays in 35 mm dishes and scored the number of viable cells after 7 days by Trypan Blue exclusion. Expansion rate of NSCs was determined using a linear regression model and difference in the slopes (P value) was determined by the analysis of covariance (ANCOVA) using Prism 6.0 (GraphPad). Limiting dilution assay (LDA) for human GSCs was performed as described previously 45 . Briefly, spheres were dissociated into single cells and plated into 96-well plates in 0.2 ml of medium containing growth factors at increasing densities (1-100 cells per well) in triplicate. Cultures were left undisturbed for 14 days, and then the percent of wells not containing spheres for each cell dilution was calculated and plotted against the number of cells per well. Linear regression lines were plotted, and we estimated the minimal frequency of glioma cells endowed with stem cell capacity (the number of cells required to generate at least one sphere in every well = the stem cell frequency) based on the Poisson distribution and the intersection at the 37% level using Prism 6.0 software. Data represent the means of three independent experiments performed in different days for the evaluation of the effects of ID2, ID2(T27A) in the presence or in the absence of DYRK1B. LDA for the undegradable HIF2α rescue experiment was performed by using three cultures transduced independently on the same day. Identification of phosphorylation sites of ID2. To identify the sites of ID2 phosphorylation from IMR32 human neuroblastoma cells, the immunoprecipitated ID2 protein was excised, digested with trypsin, chymotrypsin and Lys-C and the peptides extracted from the polyacrylamide in two 30 μl aliquots of 50% acetonitrile/ 5% formic acid. These extracts were combined and evaporated to 25 μl for MS analysis. The LC-MS system consisted of a state-of-the-art Finnigan LTQ-FT mass spectrometer system with a Protana nanospray ion source interfaced to a self-packed 8 cm × 75 μm id Phenomenex Jupiter 10 μm C18 reversed-phase capillary column. 0.5-5 μl volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1 M acetic acid gradient at a flow rate of 0.25 μl min −1 . The nanospray ion source was operated at 2.8 kV. The digest was analysed using the double play capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in sequential scans. This mode of analysis produces approximately 1200 CAD spectra of ions ranging in abundance over several orders of magnitude. Tandem MS/MS experiments were performed on each candidate phosphopeptide to verify its sequence and locate the phosphorylation site. A signature of a phosphopeptide is the detection of loss of 98 daltons (the mass of phosphoric acid) in the MS/MS spectrum. With this method, three phosphopeptides were found to carry phosphorylations at residues Ser5, Ser14 and Thr27 of the ID2 protein.
Generation of phospho-ID2-T27 antibody. The anti-phospho-T27-ID2 antibody was generated by immunizing rabbits with a short synthetic peptide containing the phosphorylated T27 (CGISRSK-pT-PVDDPMS) (Yenzym Antibodies, LLC). A two-step purification process was applied. First, antiserum was cross-absorbed against the phospho-peptide matrix to purify antibodies that recognize the phosphorylated peptide. Then, the anti-serum was purified against the un-phosphorylated peptide matrix to remove non-specific antibodies. Immunoblot, immunoprecipitation and in vitro binding assay. Cells were lysed in NP40 lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 1.5 mM Na 3 VO 4 , 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM β-glycerolphosphate and EDTA-free protease inhibitor cocktail (Roche)) or RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.5% sodium dexoycholate, 0.1% sodium dodecyl sulphate, 1.5 mM Na 3 VO 4 , 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM β-glycerolphosphate and EDTA-free protease inhibitor cocktail (Roche)). Lysates were cleared by centrifugation at 15,000 r.p.m. for 15 min at 4 °C. For immunoprecipitation, cell lysates were incubated with primary antibody (hydroxyproline, Abcam, ab37067; VHL, BD, 556347; DYRK1A, Cell Signaling Technology, 2771; DYRK1B, Cell Signaling Technology, 5672) and protein G/A beads (Santa Cruz, sc-2003) or phospho-Tyrosine (P-Tyr-100) Sepharose beads (Cell Signaling Technology, 9419), HA affinity matrix (Roche, 11815016001), Flag M2 affinity gel (Sigma, F2426) at 4 °C overnight. Beads were washed with lysis buffer four times and eluted in 2× SDS sample buffer. Protein samples were separated by SDS-PAGE and transferred to polyvinyl difluoride (PVDF) or nitrocellulose (NC) membrane. Membranes were blocked in TBS with 5% non-fat milk and 0.1% Tween20, and probed with primary antibodies. Antibodies and working concentrations are: ID2 1:500 (C-20, sc-489), GFP 1:1,000 (B-2, sc-9996), HIF2α/EPAS-1 1:250 (190b, sc-13596), c-MYC (9E10, sc-40), and Elongin B 1:1,000 (FL-118, sc-11447), obtained from Santa Cruz Biotechnology; phospho-Tyrosine 1:1,000 (P-Tyr-100, 9411), HA 1:1,000 (C29F4, 3724), VHL 1:500 (2738), DYRK1A 1:1,000, 2771; DYRK1B 1:1,000, 5672) and RBX1 1:2,000 (D3J5I, 11922), obtained from Cell Signaling Technology; VHL 1:500 (GeneTex, GTX101087); β-actin 1:8000 (A5441), α-tubulin 1:8,000 (T5168), and Flag M2 1:500 (F1804) obtained from Sigma; HIF1α 1:500 (H1alpha67, NB100-105) and Elongin C 1:1,000 (NB100-78353) obtained from Novus Biologicals; HA 1:1000 (3F10, 12158167001) obtained from Roche. Secondary antibodies horseradishperoxidase-conjugated were purchased from Pierce and ECL solution (Amersham) was used for detection.
For in vitro binding assays, HA-tagged RBX1, Elongin B, Elongin C and VHL were in vitro translated using TNT quick coupled transcription/translation system (Promega). Active VHL protein complex was purchased from EMD Millipore. Purified His-VHL protein was purchased from ProteinOne (Rockville, MD).
GST, GST-ID2 and Flag-ID2 proteins were bacterial expressed and purified using glutathione sepharose beads (GE healthcare life science). Active DYRK1B (Invitrogen) was used for in vitro phosphorylation of Flag-ID2 proteins. Biotinylated wild-type and modified (pT27 and T27W) ID2 peptides (amino acids were synthesized by LifeTein (Somerset, NJ). In vitro binding experi ments between ID2 and VCB-Cul2 were performed using 500 ng of Flag-ID2 and 500 ng of VCB-Cul2 complex or 500 ng VHL protein in binding buffer (50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 10 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 1.5 mM Na 3 VO 4 , 0.2% NP40, 10% glycerol, 0.1 mg ml −1 BSA and EDTA-free protease inhibitor cocktail (Roche)) at 4 °C for 3 h. In vitro binding between ID2 peptides and purified proteins was performed using 2 μg of ID2 peptides and 200 ng of recombinant VCB-Cul2 complex or 200 ng recombinant VHL in binding buffer (50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 10 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 1.5 mM Na 3 VO 4 , 0.4% NP40, 10% glycerol, 0.1 mg ml −1 BSA and EDTAfree protease inhibitor cocktail (Roche)) at 4 °C for 3 h or overnight. Protein complexes were pulled down using glutathione sepharose beads (GE Healthcare Life Science) or streptavidin conjugated beads (Thermo Fisher Scientific) and analysed by immunoblot. In vitro and in vivo kinase assays. Cdk1, Cdk5, DYRK1A, DYRK1B, ERK, GSK3, PKA, CaMKII, Chk1, Chk2, RSK-1, RSK-2, aurora-A, aurora-B, PLK-1, PLK-2, and NEK2 were all purchased from Life Technology and ATM from EMD Millipore. The 18 protein kinases tested in the survey were selected because they are proline-directed S/T kinases (Cdk1, Cdk5, DYRK1A, DYRK1B, ERK) and/or because they were considered to be candidate kinases for Thr27, Ser14 or Ser5 from kinase consensus prediction algorithms (NetPhosK1.0, http://www.cbs.dtu. In vivo kinase assay in GSCs and glioma cells was performed using endogenous or exogenously expressed DYRK1A and DYRK1B. Cell lysates were prepared in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 1.5 mM Na 3 VO 4 , 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM β-glycerolphosphate and EDTA-free protease inhibitor cocktail (Roche)). DYRK1 kinases were immunoprecipitated using DYRK1A and DYRK1B antibodies (for endogenous DYRK1 proteins) or GFP antibody (for exogenous GFP-DYRK1 proteins) from 1 mg cellular lysates at 4 °C. Immunoprecipitates were washed with lysis buffer four times followed by two washes in kinase buffer as described above and incubated with 200 ng purified Flag-ID2 protein in kinase buffer for 30 min at 30 °C. Kinase reactions were separated by SDS-PAGE and analysed by western blot using p-T27-ID2 antibody. Protein half-life and stoichiometry. HIF2α half-life was quantified using ImageJ processing software (NIH). Densitometry values were analysed by Prism 6.0 using the linear regression function. Stoichiometric quantification of ID2 and VHL in U87 cells was obtained using recombinant Flag-ID2 and His-tagged-VHL as references. The chemiluminescent signal of serial dilutions of the recombinant proteins was quantified using ImageJ, plotted to generate a linear standard curve against which the densitometric signal generated by serial dilutions of cellular lysates (1 × 10 6 U87 cells) was calculated. Triplicate values ± s.e.m. were used to estimate the ID2:VHL ratio per cell. The stoichiometry of pT27-ID2 phosphorylation was determined as described 46 . Briefly, SK-N-SH cells were plated at density of 1 × 10 6 in 100 mm dishes. Forty-eight hours later 1.5 mg of cellular lysates from cells untreated or treated with CoCl 2 during the previous 24 h were prepared in RIPA buffer and immunoprecipitated using 4 μg of pT27-ID2 antibody or rabbit IgG overnight at 4 °C. Immune complexes were collected with TrueBlot anti-rabbit IgG beads (Rockland), washed 5 times in lysis buffer, and eluted in SDS sample buffer. Serial dilutions of cellular lysates, IgG and pT27-ID2 immunoprecipitates were loaded as duplicate series for SDS-PAGE and western blot analysis using ID2 or p-T27-ID2 antibodies. Densitometry quantification of the chemiluminescent signals was used to determine (1) the efficiency of the immunoprecipitation using the antibody against p-ID2-T27 and (2) the ratio between efficiency of the immunoprecipitation evaluated by western blot for p-T27-ID2 and total ID2 antibodies.
This represents the percent of phosphorylated Thr27 of ID2 present in the cell preparation. Identification of ID2 complexes by mass spectrometry. Cellular ID2 complexes were purified from the cell line NCI-H1299 stably engineered to express Flag-HA-ID2. Cellular lysates were prepared in 50 mM Tris-HCl, 250 mM NaCl, 0.2% NP40, 1 mM EDTA, 10% glycerol, protease and phosphatase inhibitors. Flag-HA-ID2 immunoprecipitates were recovered first with anti-Flag antibody-conjugated M2 agarose (Sigma) and washed with lysis buffer containing 300 mM NaCl and 0.3% NP40. Bound polypeptides were eluted with Flag peptide and further affinity purified by anti-HA antibody-conjugated agarose (Roche). The eluates from the HA beads were analysed directly on long gradient reverse phase LC-MS/ MS. A specificity score of proteins interacting with ID2 was computed for each polypeptide by comparing the number of peptides identified from mass spectrometry analysis to those reported in the CRAPome database that includes a list of potential contaminants from affinity purification-mass spectrometry experiments (http://www.crapome.org). The specificity score is computed as [(#peptide* #xcorr)/(AveSC*MaxSC* # of Expt.)], #peptide, identified peptide count; #xcorr, the cross-correlation score for all candidate peptides queried from the database; AveSC, averaged spectral counts from CRAPome; MaxSC, maximal spectral counts from CRAPome; and # of Expt., the total found number of experiments from CRAPome. Ubiquitylation assay. U87 cells were transfected with pcDNA3-HA-HIFα (HIF1α or HIF2α), pcDNA3-Flag-ID2 (WT or T27A), pEGFP-DYRK1B and pcDNA3-Myc-Ubiquitin. 36 h after transfection, cells were treated with 20 μM MG132 (EMD Millipore) for 6 h. After washing with ice-cold PBS twice, cells were lysed in 100 μl of 50 mM Tris-HCl pH 8.0, 150 mM NaCl (TBS) containing 2% SDS and boiled at 100 °C for 10 min. Lysates were diluted with 900 μl of TBS containing 1% NP40. Immunoprecipitation was performed using 1 mg of cellular lysates. Ubiquitylated proteins were immunoprecipitated using anti-Myc antibody and analysed by western blot using HA antibody. Docking of ID2 peptide to the VCB complex. A previously described 47 , highly accurate flexible peptide docking method implemented in ICM software (Molsoft LLC, La Jolla CA) was used to dock ID2 peptides to VCB or components thereof. A series of overlapping peptides of varying lengths were docked to the complex of VHL and Elongin C (EloC), or VHL or EloC alone, from the recent crystallographic structure 22 of the VHL-CRL ligase. Briefly, an all-atom model of the peptide was docked into grid potentials derived from the X-ray structure using a stochastic global optimization in internal coordinates with pseudo-Brownian and collective 'probability-biased' random moves as implemented in the ICM program. Five types of potentials for the peptide-receptor interaction energy -hydrogen van der Waals, non-hydrogen van der Waals, hydrogen bonding, hydrophobicity and electrostatics -were precomputed on a rectilinear grid with 0.5 Å spacing that fills a 34 Å × 34 Å × 25 Å box containing the VHL-EloC (V-C) complex, to which the peptide was docked by searching its full conformational space within the space of the grid potentials. The preferred docking conformation was identified by the lowest energy conformation in the search. The preferred peptide was identified by its maximal contact surface area with the respective receptor.
ab initio folding and analysis of the peptides was performed as previously described 48, 49 . ab initio folding of the ID2 peptide and its phospho-T27 mutant showed that both strongly prefer an α-helical conformation free (unbound) in solution, with the phospho-T27 mutant having a calculated free energy almost 50 kcal-equivalent units lower than the unmodified peptide. RT-PCR. Total RNA was prepared with Trizol reagent (Invitrogen) and cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen) as described 42, 50 . Semi-quantitative RT-PCR was performed using AccuPrime Taq DNA polymerase (Invitrogen) and the following primers: for HIF2A Fw 5′_GTGCTCCCACGGCCTGTA_3′ and Rv 5′_TTGTCA CACCTATGGCATATCACA_3′; GAPDH Fw 5′_AGAAGGCTGGGGC TCATTTG_3′ and Rv 5′_AGGGGCCATCCACAGTCTTC_3′. The quantitative RT-PCR was performed with a Roche480 thermal cycler, using SYBR Green PCR Master Mix from Applied Biosystem.
Primers used in qRT-PCR are: SOX2 Fw 5′_TTGCTGCCTCTTTAA GACTAGGA_3′ and Rv 5′_CTGGGGCTCAAACTTCTCTC_3′; NANOG Fw 5′_ATGCCTCACACGGAGACTGT_3′ and Rv 5′_AAGTGGGTTGTTTGC CTTTG_3′; POU5F1 Fw 5′_GTGGAGGAAGCTGACAACAA_3′ and Rv 5′_ATTCTCCAGGTTGCCTCTCA_3′; FLT1 Fw 5′_AGCCCATA AATGGTCTTTGC_3′ and Rv 5′_GTGGTTTGCTTGAGCTGTGT_3′; PIK3CA Fw 5′_TGCAAAGAATCAGAACAATGCC_3′ and 5′_CACGGAGGCATT CTAAAGTCA_3′; BMI1 Fw 5′_AATCCCCACCTGATGTGTGT_3′ and Rv 5′_GCTGGTCTCCAGGTAACGAA_3′; GAPDH Fw 5′_GAAGGTGAAG GTCGGAGTCAAC_3′ and Rv 5′_CAGAGTTAAAAGCAGCCCTGGT_3′; 18S Fw 5′_CGCCGCTAGAGGTGAAATTC_3′ and Rv 5′_CTTTCGC TCTGGTCCGTCTT_3′. The relative amount of specific mRNA was normalized Article reSeArcH to 18S or GAPDH. Results are presented as the mean ± s.d. of three independent experiments each performed in triplicate (n = 9). Statistical significance was determined by Student's t-test (two-tailed) using GraphPad Prism 6.0 software. Subcutaneous and intracranial xenograft glioma models. Mice were housed in pathogen-free animal facility. All animal studies were approved by the IACUC at Columbia University (numbers AAAE9252; AAAE9956). Mice were 4-6-week-old male athymic nude (Nu/Nu, Charles River Laboratories). No statistical method was used to pre-determine sample size. No method of randomization was used to allocate animals to experimental groups. Mice in the same cage were generally part of the same treatment. The investigators were not blinded during outcome assessment. In none of the experiments did tumours exceed the maximum volume allowed according to our IACUC protocol, specifically 20 mm in the maximum diameter. 2 × 10 5 U87 cells stably expressing a doxycycline inducible lentiviral vector coding for DYRK1B or the empty vector were injected subcutaneously in the right flank in 100 μl volume of saline solution (7 mice per each group). Mice carrying 150-220 mm 3 subcutaneous tumours (21 days after injection) generated by cells transduced with DYRK1B were treated with vehicle or doxycycline by oral gavage (Vibramycin, Pfizer Labs; 8 mg ml −1 , 0.2 ml per day) 51 ; mice carrying tumours generated by cells transduced with the empty vector were also fed with doxycycline. Tumour diameters were measured daily with a caliper and tumour volumes estimated using the formula: width 2 × length/2 = V (mm 3 ). Mice were euthanized after 5 days of doxycycline treatment. Tumours were dissected and fixed in formalin for immunohistochemical analysis. Data are means ± s.d. of 7 mice in each group. Statistical significance was determined by ANCOVA using GraphPad Prism 6.0 software package (GraphPad).
Orthotopic implantation of glioma cells was performed as described previously using 5 × 10 4 U87 cells transduced with pLOC-vector, pLOC-DYRK1B (WT) or pLOC-DYRK1B-K140R mutant in 2 μl phosphate buffer 42 . In brief, 5 days after lentiviral infection, cells were injected 2 mm lateral and 0.5 mm anterior to the bregma, 2.5 mm below the skull of 4-6-week-old athymic nude (Nu/Nu, Charles River Laboratories) mice. Mice were monitored daily for abnormal ill effects according to AAALAS guidelines and euthanized when neurological symptoms were observed. Tumours were dissected and fixed in formalin for immunohistochemical analysis and immunofluorescence using V5 antibody (Life technologies, 46-0705) to identify exogenous DYRK1B and an antibody against human vimentin (Sigma, V6630) to identify human glioma cells. A Kaplan-Meier survival curve was generated using the GraphPad Prism 6.0 software package (GraphPad). Points on the curves indicate glioma related deaths (n = 7 animals for each group, p was determined by log rank analysis). We did not observe non-glioma related deaths. Mice injected with U87 cells transduced with pLOC-DYRK1B(WT) that did not show neurological signs on day 70 were euthanized for histological evaluation and shown as tumour-free mice in Fig. 5g . Intracranial injection of H-Ras-V12-IRES-Cre-ER-shp53 lentivirus was performed in 4-week-old Id1 Flox/Flox , Id2 Flox/Flox , Id3 −/− mice (C57Bl6/SV129). Briefly, 1.3 μl of purified lentiviral particles in PBS were injected 1.45 mm lateral and 1.6 mm anterior to the bregma and 2.3 mm below the skull using a stereotaxic frame. Tamoxifen was administered for 5 days at 9 mg per 40 g of mouse weight by oral gavage starting 30 days after surgery. Mice were killed 2 days later and brains dissected and fixed for histological analysis. Immunohistochemistry and immunofluorescence. Tissue preparation and immunohistochemistry on tumour xenografts were performed as previously described 42, 50, 52 . Antibodies used in immunostaining are: HIF2α, mouse monoclonal, 1:200 (Novus Biological, NB100-132); Olig2, rabbit polyclonal, 1:200 (IBL International, JP18953); human Vimentin 1:50 (Sigma, V6630), Bromodeoxyuridine, mouse monoclonal 1:500 (Roche, 11170376001), V5 1:500 (Life technologies, 46-0705). Sections were permeabilized in 0.2% tritonX-100 for 10 min, blocked with 1% BSA-5% goat serum in PBS for 1 h. Primary antibodies were incubated at 4 °C overnight. Secondary antibodies biotinylated (Vector Laboratories) or conjugated with Alexa594 (1:500, Molecular Probes) were used. Slides were counterstained with haematoxylin for immunohistochemistry and DNA was counterstained with DAPI (Sigma) for immunofluorescence. Images were acquired using an Olympus 1X70 microscope equipped with digital camera and processed using Adobe Photoshop CS6 software. BrdU-positive cells were quantified by scoring the number of positive cells in five 4 × 10 −3 mm 2 images from 5 different mice from each group. Blinding was applied during histological analysis. Data are presented as means of five different mice ± standard deviation (s.d.) (two-tailed Student's t-test, unequal variance).
Computational analysis of dependency of the HIF2α regulon on ID2 activity.
To infer if ID2 modulates the interactions between HIF2α and its transcriptional targets we used a modified version of MINDy 53 algorithm, called CINDy 25 . CINDy uses adaptive partitioning method to accurately estimate the full conditional mutual information between a transcription factor and a target gene given the expression or activity of a signalling protein. Briefly, for every pair of transcription factor and target gene of interest, it estimates the mutual information that is, how much information can be inferred about the target gene when the expression of the transcription factor is known, conditioned on the expression/activity of the signalling protein. It estimates this conditional mutual information by estimating the multidimensional probability densities after partitioning the sample distribution using adaptive partitioning method. We applied CINDy algorithm on gene expression data for 548 samples obtained from The Cancer Genome Atlas (TCGA). Since the activity level and not the gene expression of ID2 is the determinant of its modulatory function that is, the extent to which it modulates the transcriptional network of HIF2α, we used an algorithm called Virtual Inference of Protein-activity by Enriched Regulon analysis (VIPER) to infer the activity of ID2 protein from its gene expression profile 26 . VIPER method allows the computational inference of protein activity, on an individual sample basis, from gene expression profile data. It uses the expression of genes that are most directly regulated by a given protein, such as the targets of a transcription factor (TF), as an accurate reporter of its activity. We defined the targets of ID2 by running ARACNe algorithm on 548 gene expression profiles and use the inferred 106 targets to determine its activity (Supplementary Table 3 ).
We applied CINDy on 277 targets of HIF2α represented in Ingenuity pathway analysis (IPA) and for which gene expression data was available (Supplementary Table 4 ). Of these 277 targets, 77 are significantly modulated by ID2 activity (P value ≤ 0.05). Among the set of target genes whose expression was significantly positively correlated (P value ≤ 0.05) with the expression of HIF2α irrespective of the activity of ID2, that is, correlation was significant for samples with both high and low activity of ID2, the average expression of target genes for a given expression of HIF2α was higher when the activity of ID2 was high. The same set of target gene were more correlated in high ID2 activity samples compared to any set of random genes of same size (Fig. 5a ), whereas they were not in ID2 low activity samples (Fig. 5b) . We selected 25% of all samples with the highest/lowest ID2 activity to calculate the correlation between HIF2α and its targets.
To determine whether regulation of ID2 by hypoxia might impact the correlation between high ID2 activity and HIF2α shown in Fig. 5a, b we compared the effects of ID2 activity versus ID2 expression for the transcriptional connection between HIF2α and its targets. We selected 25% of all patients (n = 548) in TCGA with high ID2 activity and 25% of patients with low ID2 activity and tested the enrichment of significantly positively correlated targets of HIF2α in each of the groups. This resulted in significant enrichment (P value < 0.001) in high ID2 activity but showed no significant enrichment (P value = 0.093) in low ID2 activity samples. Moreover, the difference in the enrichment score (ΔES) in these two groups was statistically significant (P value < 0.05). This significance is calculated by randomly selecting the same number of genes as the positively correlated targets of HIF2α, and calculating the ΔES for these randomly selected genes, giving ΔES rand . We repeated this step 1,000 times to obtain 1,000 ΔES rand that are used to build the null distribution (Extended Data Fig. 9b ). We used the null distribution to estimate P value calculated as (number of ΔES > ΔES rand )/1,000. Enrichment was observed only when ID2 activity was high but not when ID2 activity was low, thus suggesting that ID2 activity directionally impacts the regulation of targets of HIF2α by HIF2α. Consistently, the significant ΔES using ID2 activity suggests that ID2 activity is determinant of correlation between HIF2α and its targets.
Conversely, when we performed similar analysis using ID2 expression instead of ID2 activity, we found significant enrichment of positively correlated targets of HIF2α both in samples with high expression (P value = 0.025) and low expression of ID2 (P value = 0.048). Given the significant enrichment in both groups, we did not observe any significant difference in the enrichment score in the two groups (P value of ΔES = 0.338). Thus, while the determination of the ID2 activity and its effects upon the HIF2α-targets connection by VIPER and CINDy allowed us to determine the unidirectional positive link between high ID2 activity and HIF2α transcription, a similar analysis performed using ID2 expression contemplates the dual connection between ID2 and HIF2α. Kaplan-Meier analysis for DYRK1A and DYRK1B in human GBM. To test if expression of DYRK1A and DYRK1B is a predictor of prognosis, we divided the patients into two cohorts based on their relative expression compared to the mean expression of all patients in GBM. First cohort contained the patients with high expression of both DYRK1A and DYRK1B (n = 101) and the other cohort contained patients with low expression (n = 128). We used average expression for both DYRK1A and DYRK1B, which individually divide the patient cohort into half and half. However, when we use the condition that patients should display higher or lower average expression of both these genes, then we select approximately 19% for high expression and 24% for low expression. Selection of these patients was entirely dependent on the overall expression of these genes in the entire cohort rather than a predefined cutoff. Kaplan-Meier survival analysis showed the significant survival benefit for the patients having the high expression of both DYRK1A and DYRK1B (P value = 0.004) compared to the patients with low expression. 
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